Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Abbott Laboratories (NY:ABT)

131.69 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
Nasdaq Sees Worst Session Since 2022 As Chip Stocks Tumble After Trump's Taiwan Remarks and Biden's Potential Restrictions
The CNN Money Fear and Greed index showed a decline in the overall market sentiment, with the index moving to the "Neutral" zone on Wednesday. 
Via Benzinga
Topics Government
Exposures Political
D.R. Horton, Netflix And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
Abbott Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Via Benzinga
Dow Closes At New High As Q2 Earnings Season Heats Up
It’s a great start to the trading week. After months of trailing its major-index brethren, the Dow Jones reaches today’s closing bell at a new record high: 40,211. Q2 earnings are coming in well so... 
Via Talk Markets
Topics Stocks
Exposures US Equities
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
Explore undervalued healthcare stocks offering growth potential and stability in contrast to overvalued tech sector. 
Via InvestorPlace
Looking Into Abbott Laboratories's Recent Short Interest
Via Benzinga
7 Analysts Have This To Say About Abbott Laboratories
Via Benzinga
Market Whales and Their Recent Bets on ABT Options
Via Benzinga
Netflix, Goldman Sachs, J&J, ASML Lead Q2 Reports This Week As Analysts See Earnings Growth Accelerating To Fastest In Over 2 Years
Following a lackluster big bank earnings, market participants now turn their attention to the unfolding week, expecting the trend to reverse. 
Via Benzinga
U.S. Cannabis Market Soars Amid Legal Reforms, But Safety Concerns Persist
From Financial Buzz Media
Via GlobeNewswire
Abbott Laboratories's Options: A Look at What the Big Money is Thinking
Via Benzinga
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
These are the healthcare stocks to buy as they represent companies with good fundamentals, stable growth visibility and cash flow upside. 
Via InvestorPlace
Similac Baby Formula Maker Abbott And Reckitt Face Hundreds Of Baby Formula Lawsuits
Abbott faces trial over claims its baby formula causes necrotizing enterocolitis in preterm infants. This is the second trial among hundreds of similar lawsuits, impacting Abbott and Reckitt... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
The 3 Best Healthcare Stocks to Buy in July 2024
Consistent breakthroughs, improved products and relatively consistent growth make these the best healthcare stocks to buy. 
Via InvestorPlace
AbbVie Stock: A Perfect Dip for Investors to Buy
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors 
Via MarketBeat
Topics ETFs
7 Dividend Aristocrats That Will Have Investors in High-Yield Heaven
These Dividend Aristocrats all have payouts yielding three times or more the average yield of the S&P 500. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
3 MedTech Stocks to Buy for Healthy Gains
With innovations in healthcare moving at a rapid clip, investors should consider these enticing MedTech stocks to buy. 
Via InvestorPlace
Stocks Going Ex Dividend In July 2024
This article features a short list of some of the many stocks going ex-dividend during the next month, which can be helpful for traders and investors interested in the stock trading technique known as... 
Via Talk Markets
Hot Summer Dividends: 3 Sizzling Stocks to Buy for Reliable Income
Buying dividend stocks for income is a smart investment strategy to juice your portfolio's returns even in down markets. 
Via InvestorPlace
Top Analyst Reports For Abbott, BP & Gilead
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories, BP p.l.c.and Gilead Sciences, Inc., as well as two micro-cap stocks Smith-Midland Corp. and... 
Via Talk Markets
10 Stocks to Build a Dividend Portfolio That Will Pay You $1,000s per Year
The power of compounding can build huge amounts of passive income. 
Via The Motley Fool
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
These healthcare players offer you dividends and a strong earnings picture. 
Via The Motley Fool
2 Healthcare Stocks to Buy Hand Over Fist in June
They both have pretty impressive pasts, and their prospects look just as bright. 
Via The Motley Fool
2 Magnificent Dividend Growth Stocks to Buy Now
These two dividend growth stocks are potent capital appreciation vehicles. 
Via The Motley Fool
Abbott Snags U.S. Clearance To Enter The Obesity Arena, Rivaling Dexcom
The FDA clearance for two new CGMs puts Abbott on track to rival Dexcom's new Stelo device. 
Via Investor's Business Daily
Exposures Product Safety
Class Action Against Abbott's Glucerna Products Proceeds in Federal Court
WuXi AppTec employees collaborated with China's PLA on altitude sickness drugs, raising national security concerns in the U.S. Congressional committee calls for restricting biotech ties amid ongoing... 
Via Benzinga
The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash
Dividend stocks have a record of stability and growth. Read here about three picks that are thriving and hiking dividends amid uncertainty. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Berkshire Hathaway, Chipotle, More NYSE Stocks Hit With Trading Halts Triggered By Technical Issues
NYSE experiences trading halts Monday due to a technical issue. Stocks like Berkshire Hathaway and Chipotle are impacted. 
Via Benzinga
Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals?
Vertex might not present a clear and present danger to Abbott and DexCom but could present a clear future threat. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.